TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed treatment in the blinded phase of their late-stage clinical trial, Lucidity (NCT03446001).

This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM). The topline results are due to be announced in May.

According to AD International, around 50 million people are affected by dementia worldwide, and in 2050 this will rise to 152 million – with AD being the most common form.

Lucidity is the only late-stage clinical trial specifically targeting the tau pathology of AD. Aggregation of abnormal tau is a hallmark of AD. Tau aggregation and the formation of tau tangles disrupt neuronal function, a process that begins years before dementia symptoms are seen. Tau pathology correlates strongly with AD severity and the clinical decline commonly seen in patients.